Fused heterocyclic compounds as ion channel modulators

Patent metadata

Field	Value
Publication number	US-9676760-B2
Application number	US-201615152231-A
Country	US
Kind code	B2
Filing date	May 11, 2016
Priority date	Jul 1, 2011
Publication date	Jun 13, 2017
Grant date	Jun 13, 2017

Abstract

The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I:

wherein Z 1 , Z 2 , Z 3 , Z 4 , X, Y, R 2 , R 3 and R 4 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

First claim

What is claimed is:

1. A compound of formula:

2. A pharmaceutical composition comprising a compound of formula:

and a pharmaceutically acceptable carrier.

Assignees

• Gilead Sciences Inc

Inventors

• Corkey Britton Kenneth
• Elzein Elfatih
• Graupe Michael
• Guerrero Juan
• Jiang Robert H
• Kalla Rao V
• Koltun Dmitry
• Li Xiaofen
• Martinez Ruben
• Parkhill Eric Q
• Perry Thao
• Venkataramani Chandrasekar
• Zablocki Jeff

Classifications

• A61P9/06

  Antiarrhythmics · CPC title

• A61P9/12

  Antihypertensives · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P5/00

  Drugs for disorders of the endocrine system · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title